Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers

Next Previous
Trial Profile

Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary)
  • Indications Insulinoma; Neuroendocrine carcinoma; Neuroendocrine tumours
  • Focus Therapeutic Use

Most Recent Events

  • 16 May 2016 Protocol has been amended to change in primary endpoints from "Time to response" to "Number of Participants With Partial Response (PR)" and "Number of Participants With Complete Response (CR)".
  • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 22 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top